Secondary Hyperparathyroidism: A Hidden Danger in Chronic Kidney Disease

Secondary Hyperparathyroidism: A Hidden Danger in Chronic Kidney Disease

Chapter 1: Assessing Patients with CKD for SHPT

3 chapters
Play All
ReachMD Healthcare Image
Media formats available:
Program chapters
  • Overview

    Please note:This activity is no longer available for continuing education credit.

    A high percentage of patients with chronic kidney disease have low levels of vitamin D leading to secondary hyperparathyroidism (SHPT), which plays a critical role in the development of chronic kidney disease-mineral and bone disorder (CKD-MBD). Our experts, Dr. Mario Cozzolino and Dr. Jan Kielstein, discuss the complexity of the condition, early diagnosis, treatment goals, and emerging therapies. Tune in to be sure you’re using all the tools at your disposal to improve your patients’ quality of life.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Mario Cozzolino, MD, PhD
    Professor of Nephrology
    University of Milan
    Milan, Italy

    Consulting Fees: Amgen, Baxter, CSL Vifor Pharma

    Jan T. Kielstein, MD, FASN, FERA
    Director, Academic Teaching Hospital Braunschweig
    Magdeburg, Germany

    Research: ExThera Medical
    Ownership Interest: Bayer, CureVac, Quanterix, SYNLAB
    Consulting Fees: Bayer, Berlin-Chemie, Fresenius Medical Care, Vifor Pharma

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Hany Ibrahim, MD, has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Katie Sheridan, PhD, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Assess patients with chronic kidney disease (CKD) for secondary hyperparathyroidism (SHPT)
    • Describe the mechanisms by which mineral bone disorders associated with CKD can lead to vascular calcification
    • Describe how to initiate and monitor treatment of SHPT with extended-release vitamin D therapies
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

Facebook Comments



We’re glad to see you’re enjoying Global Kidney Academy…
but how about a more personalized experience?

Register for free